Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 63.96% is 47% above its 5-year average of 43.55%, near the low end of its 5-year range (0.00%–679.55%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.13% below its 12-month average of 64.69%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 63.96%.
DEBT TO ASSETS RATIO
63.96%
DEBT TO ASSETS RATIO AVG TTM
64.69%
DEBT TO ASSETS RATIO AVG 3Y
56.03%
DEBT TO ASSETS RATIO AVG 5Y
43.55%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-1.13%
CURRENT VS 3Y AVG
+14.14%
CURRENT VS 5Y AVG
+46.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 602 covered companies
CURRENT VS SECTOR MEDIAN
+63857.79%
vs the sector median at left
Lucid Diagnostics Inc.
Market Cap
$112.17M
Debt to Assets Ratio
63.96%
TTM Avg
64.69%
3Y Avg
56.03%
5Y Avg
43.55%
Market Cap
$111.89M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.38M
Debt to Assets Ratio
0.21%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.57M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.49M
Debt to Assets Ratio
0.65%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$109.20M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$115.76M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.50M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucid Diagnostics Inc. (LUCD) | $112.17M | 63.96% | 64.69% | 56.03% | 43.55% |
| Coya Therapeutics, Inc. (COYA)vs › | $111.89M | 0.00% | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $110.38M | 0.21% | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $114.57M | 0.09% | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | 0.09% | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.49M | 0.65% | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.20M | 0.01% | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $115.76M | 0.09% | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.50M | 0.19% | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.64M | 0.00% | N/A | N/A | N/A |
Debt/Assets
64.0%
Debt/Equity
2.28
Current Ratio
1.33
Interest Coverage
-2256.4x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 63.96% |
| 2026-03-31 | 78.65% |
| 2025-12-31 | 63.84% |
| 2025-09-30 | 45.74% |
| 2025-06-30 | 71.25% |
| 2025-03-31 | 107.55% |
| 2024-12-31 | 69.20% |
| 2024-09-30 | 57.82% |
| 2024-06-30 | 41.74% |
| 2024-03-31 | 44.24% |
| 2023-12-31 | 55.94% |
| 2023-09-30 | 48.38% |
| 2023-06-30 | 31.64% |
| 2023-03-31 | 28.04% |
| 2022-12-31 | 6.15% |
| 2022-09-30 | 5.22% |
| 2022-06-30 | 4.58% |
| 2022-03-31 | 3.58% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 679.55% |
| 2021-06-30 | 463.06% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2018-12-31 | 0.00% |
